Neurotoxic target for amylospheroid, method and material for reducing the neurotoxicity of amylospheroid, and use thereof
View Patent ↗In one or a plurality of embodiments, there is provided a target molecule of amylospheroid, which is expressed in mature neurons and to which the amylospheroid binds to induce death of cells. Further, in one or a plurality of embodiments, there is provided a method and a substance for inhibiting death of mature neurons induced by the amylospheroid. In one aspect, the present disclosure relates to a use of Na + /K + -ATPase α3 as a binding target molecule of amylospheroid. In another aspect, the present disclosure relates to a method for suppressing death of mature neurons induced by the amylospheroid, including inhibiting protein-protein interaction between the amylospheroid and the Na + /K + -ATPase α3, and the like.
1. A method for inhibiting protein-protein interaction between amylospheroid and Na + /K + -ATPase α3, consisting of causing at least one substance selected from a group consisting of a polypeptide, a peptide mimetic thereof, and anti-NAKα3 antibody to interact with ASPD or NAKα3, wherein length of the polypeptide is 50 or less amino acids, and wherein the polypeptide comprises the amino acid sequence of X 1 X 2 NW (SEQ ID NO:8) or X 2 NW (SEQ ID NO:49) at the N-terminal, wherein X 1 is arginine, histidine, or lysine, and X 2 is hydrophobic amino acid residue or glycine.
2. A method according to claim 1 , wherein the substance mimics a tertiary structure of a site of ASPD or NAKα3 participating in the protein-protein interaction between ASPD and NAKα3.
3. A method for suppressing death of a mature neuron induced by amylospheroid, comprising inhibiting protein-protein interaction between the amylospheroid and Na + /K + -ATPase α3 by administering to a subject in need thereof at least one substance selected from a group consisting of a polypeptide, a peptide mimetic thereof, and anti-NAKα3 antibody, wherein length of the polypeptide is 50 or less amino acids, and wherein the polypeptide comprises the amino acid sequence of X 1 X 2 NW (SEQ ID NO:8) or X 2 NW (SEQ ID NO:49) at the N-terminal, wherein X 1 is arginine, histidine, or lysine, and X 2 is hydrophobic amino acid residue or glycine.
4. A method according to claim 3 , wherein the protein-protein interaction between the amylospheroid and the Na + /K + -ATPase α3 is inhibited by contact between the amylospheroid and the substance capable of performing competitive inhibition based on a surface tertiary structure of both or one of the amylospheroid and the Na + /K + -ATPase α3.
5. A method according to claim 3 , wherein the protein-protein interaction between the amylospheroid and the Na + /K + -ATPase α3 is inhibited by contact between the amylospheroid and the substance capable of binding to the amylospheroid by competition with the Na + /K + -ATPase α3.
6. A method for preventing, ameliorating, and/or treating Alzheimer's disease and/or dementia with Lewy bodies, comprising suppressing death of a mature neuron induced by amylospheroid by inhibiting protein-protein interaction between the amylospheroid and Na + /K + -ATPase α3 by administering to a subject in need thereof at least one substance selected from a group consisting of a polypeptide, a peptide mimetic thereof, and anti-NAKα3 antibody, wherein length of the polypeptide is 50 or less amino acids, and wherein the polypeptide comprises the amino acid sequence of X 1 X 2 NW (SEQ ID NO: 8) or X 2 NW (SEQ ID NO: 49) at the N-terminal, wherein X 1 is arginine, histidine, or lysine, and X 2 is hydrophobic amino acid residue or glycine.
7. A method according to claim 6 , wherein the protein-protein interaction between the amylospheroid and the Na + /K + -ATPase α3 is inhibited by contact between the amylospheroid and the substance capable of performing competitive inhibition based on a surface tertiary structure of both or one of the amylospheroid and the Na + /K + -ATPase α3.
8. A method according to claim 6 , wherein the protein-protein interaction between the amylospheroid and the Na + /K + -ATPase α3 is inhibited by contact between the amylospheroid and the substance capable of binding to the amylospheroid by competition with the Na + /K + -ATPase α3.